Modelling the health-economic impact of the next influenza pandemic in The Netherlands.
Identifieur interne : 000337 ( Main/Exploration ); précédent : 000336; suivant : 000338Modelling the health-economic impact of the next influenza pandemic in The Netherlands.
Auteurs : E. Hak [Pays-Bas] ; M J Meijboom ; E. BuskensSource :
- Vaccine [ 0264-410X ] ; 2006.
Descripteurs français
- KwdFr :
- Adulte (MeSH), Adulte d'âge moyen (MeSH), Analyse coût-bénéfice (MeSH), Grippe humaine (mortalité), Grippe humaine (prévention et contrôle), Grippe humaine (traitement médicamenteux), Grippe humaine (économie), Hospitalisation (statistiques et données numériques), Hospitalisation (économie), Humains (MeSH), Pays-Bas (épidémiologie), Planification des mesures d'urgence en cas de catastrophe (MeSH), Soins ambulatoires (économie), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (économie), Épidémies de maladies (prévention et contrôle), Épidémies de maladies (économie).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- mortalité : Grippe humaine.
- prévention et contrôle : Grippe humaine, Épidémies de maladies.
- statistiques et données numériques : Hospitalisation.
- traitement médicamenteux : Grippe humaine.
- économie : Grippe humaine, Hospitalisation, Soins ambulatoires, Vaccins antigrippaux, Épidémies de maladies.
- épidémiologie : Pays-Bas.
- Adulte, Adulte d'âge moyen, Analyse coût-bénéfice, Humains, Planification des mesures d'urgence en cas de catastrophe.
- Wicri :
- geographic : Pays-Bas.
English descriptors
- KwdEn :
- Adult (MeSH), Ambulatory Care (economics), Cost-Benefit Analysis (MeSH), Disaster Planning (MeSH), Disease Outbreaks (economics), Disease Outbreaks (prevention & control), Hospitalization (economics), Hospitalization (statistics & numerical data), Humans (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (economics), Influenza, Human (drug therapy), Influenza, Human (economics), Influenza, Human (mortality), Influenza, Human (prevention & control), Middle Aged (MeSH), Netherlands (epidemiology).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- geographic , epidemiology : Netherlands.
- drug therapy : Influenza, Human.
- economics : Ambulatory Care, Disease Outbreaks, Hospitalization, Influenza Vaccines, Influenza, Human.
- mortality : Influenza, Human.
- prevention & control : Disease Outbreaks, Influenza, Human.
- statistics & numerical data : Hospitalization.
- Adult, Cost-Benefit Analysis, Disaster Planning, Humans, Middle Aged.
Abstract
To optimally develop or adjust national contingency plans to respond to the next influenza pandemic, we developed a decision type model and estimated the total health burden and direct medical costs during the next possible influenza pandemic in the Netherlands on the basis of health care burden during a regular epidemic. Using an arithmetic decision tree-type model we took into account population characteristics, varying influenza attack rates, health care consumption according to the Dutch health care model and all-cause mortality. Actual direct medical cost estimates were based on the Dutch guidelines for pharmaco-economic evaluation. In the base-case scenario with no preventive measure available and an average influenza attack rate of 30%, 4,958,188 influenza infections, 1,552,687 GP consultations, 83,515 hospitalizations and 173,396 deaths will take place in The Netherlands. The burden is highest in adults aged 20 to 64 years. If minimizing the total mortality and sustaining highest net economic returns is the objective, this group needs to be targeted in interventions.
DOI: 10.1016/j.vaccine.2006.05.065
PubMed: 16797797
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Modelling the health-economic impact of the next influenza pandemic in The Netherlands.</title><author><name sortKey="Hak, E" sort="Hak, E" uniqKey="Hak E" first="E" last="Hak">E. Hak</name><affiliation wicri:level="1"><nlm:affiliation>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. e.hak@umcutrecht.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, P.O. Box 85500, 3508 GA Utrecht</wicri:regionArea><wicri:noRegion>3508 GA Utrecht</wicri:noRegion></affiliation></author><author><name sortKey="Meijboom, M J" sort="Meijboom, M J" uniqKey="Meijboom M" first="M J" last="Meijboom">M J Meijboom</name></author><author><name sortKey="Buskens, E" sort="Buskens, E" uniqKey="Buskens E" first="E" last="Buskens">E. Buskens</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:16797797</idno><idno type="pmid">16797797</idno><idno type="doi">10.1016/j.vaccine.2006.05.065</idno><idno type="wicri:Area/Main/Corpus">000333</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000333</idno><idno type="wicri:Area/Main/Curation">000333</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000333</idno><idno type="wicri:Area/Main/Exploration">000333</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Modelling the health-economic impact of the next influenza pandemic in The Netherlands.</title><author><name sortKey="Hak, E" sort="Hak, E" uniqKey="Hak E" first="E" last="Hak">E. Hak</name><affiliation wicri:level="1"><nlm:affiliation>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. e.hak@umcutrecht.nl</nlm:affiliation><country xml:lang="fr">Pays-Bas</country><wicri:regionArea>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, P.O. Box 85500, 3508 GA Utrecht</wicri:regionArea><wicri:noRegion>3508 GA Utrecht</wicri:noRegion></affiliation></author><author><name sortKey="Meijboom, M J" sort="Meijboom, M J" uniqKey="Meijboom M" first="M J" last="Meijboom">M J Meijboom</name></author><author><name sortKey="Buskens, E" sort="Buskens, E" uniqKey="Buskens E" first="E" last="Buskens">E. Buskens</name></author></analytic><series><title level="j">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Ambulatory Care (economics)</term><term>Cost-Benefit Analysis (MeSH)</term><term>Disaster Planning (MeSH)</term><term>Disease Outbreaks (economics)</term><term>Disease Outbreaks (prevention & control)</term><term>Hospitalization (economics)</term><term>Hospitalization (statistics & numerical data)</term><term>Humans (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (economics)</term><term>Influenza, Human (drug therapy)</term><term>Influenza, Human (economics)</term><term>Influenza, Human (mortality)</term><term>Influenza, Human (prevention & control)</term><term>Middle Aged (MeSH)</term><term>Netherlands (epidemiology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Analyse coût-bénéfice (MeSH)</term><term>Grippe humaine (mortalité)</term><term>Grippe humaine (prévention et contrôle)</term><term>Grippe humaine (traitement médicamenteux)</term><term>Grippe humaine (économie)</term><term>Hospitalisation (statistiques et données numériques)</term><term>Hospitalisation (économie)</term><term>Humains (MeSH)</term><term>Pays-Bas (épidémiologie)</term><term>Planification des mesures d'urgence en cas de catastrophe (MeSH)</term><term>Soins ambulatoires (économie)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (économie)</term><term>Épidémies de maladies (prévention et contrôle)</term><term>Épidémies de maladies (économie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>Netherlands</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Ambulatory Care</term><term>Disease Outbreaks</term><term>Hospitalization</term><term>Influenza Vaccines</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Hospitalization</term></keywords><keywords scheme="MESH" qualifier="statistiques et données numériques" xml:lang="fr"><term>Hospitalisation</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Grippe humaine</term><term>Hospitalisation</term><term>Soins ambulatoires</term><term>Vaccins antigrippaux</term><term>Épidémies de maladies</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Pays-Bas</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Cost-Benefit Analysis</term><term>Disaster Planning</term><term>Humans</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Analyse coût-bénéfice</term><term>Humains</term><term>Planification des mesures d'urgence en cas de catastrophe</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Pays-Bas</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To optimally develop or adjust national contingency plans to respond to the next influenza pandemic, we developed a decision type model and estimated the total health burden and direct medical costs during the next possible influenza pandemic in the Netherlands on the basis of health care burden during a regular epidemic. Using an arithmetic decision tree-type model we took into account population characteristics, varying influenza attack rates, health care consumption according to the Dutch health care model and all-cause mortality. Actual direct medical cost estimates were based on the Dutch guidelines for pharmaco-economic evaluation. In the base-case scenario with no preventive measure available and an average influenza attack rate of 30%, 4,958,188 influenza infections, 1,552,687 GP consultations, 83,515 hospitalizations and 173,396 deaths will take place in The Netherlands. The burden is highest in adults aged 20 to 64 years. If minimizing the total mortality and sustaining highest net economic returns is the objective, this group needs to be targeted in interventions.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">16797797</PMID><DateCompleted><Year>2007</Year><Month>01</Month><Day>23</Day></DateCompleted><DateRevised><Year>2006</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0264-410X</ISSN><JournalIssue CitedMedium="Print"><Volume>24</Volume><Issue>44-46</Issue><PubDate><Year>2006</Year><Month>Nov</Month><Day>10</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Modelling the health-economic impact of the next influenza pandemic in The Netherlands.</ArticleTitle><Pagination><MedlinePgn>6756-60</MedlinePgn></Pagination><Abstract><AbstractText>To optimally develop or adjust national contingency plans to respond to the next influenza pandemic, we developed a decision type model and estimated the total health burden and direct medical costs during the next possible influenza pandemic in the Netherlands on the basis of health care burden during a regular epidemic. Using an arithmetic decision tree-type model we took into account population characteristics, varying influenza attack rates, health care consumption according to the Dutch health care model and all-cause mortality. Actual direct medical cost estimates were based on the Dutch guidelines for pharmaco-economic evaluation. In the base-case scenario with no preventive measure available and an average influenza attack rate of 30%, 4,958,188 influenza infections, 1,552,687 GP consultations, 83,515 hospitalizations and 173,396 deaths will take place in The Netherlands. The burden is highest in adults aged 20 to 64 years. If minimizing the total mortality and sustaining highest net economic returns is the objective, this group needs to be targeted in interventions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hak</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University Medical Center Utrecht, Julius Center for Health Sciences and Primary Care, P.O. Box 85500, 3508 GA Utrecht, The Netherlands. e.hak@umcutrecht.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meijboom</LastName><ForeName>M J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Buskens</LastName><ForeName>E</ForeName><Initials>E</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000553" MajorTopicYN="N">Ambulatory Care</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003362" MajorTopicYN="N">Cost-Benefit Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004189" MajorTopicYN="Y">Disaster Planning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="Y">economics</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>1</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16797797</ArticleId><ArticleId IdType="pii">S0264-410X(06)00632-3</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2006.05.065</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Pays-Bas</li></country></list><tree><noCountry><name sortKey="Buskens, E" sort="Buskens, E" uniqKey="Buskens E" first="E" last="Buskens">E. Buskens</name><name sortKey="Meijboom, M J" sort="Meijboom, M J" uniqKey="Meijboom M" first="M J" last="Meijboom">M J Meijboom</name></noCountry><country name="Pays-Bas"><noRegion><name sortKey="Hak, E" sort="Hak, E" uniqKey="Hak E" first="E" last="Hak">E. Hak</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippePaysBasV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000337 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000337 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippePaysBasV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:16797797
|texte= Modelling the health-economic impact of the next influenza pandemic in The Netherlands.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:16797797" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippePaysBasV1
| This area was generated with Dilib version V0.6.35. |  |